Yang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Li has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Meng Yang
Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Prevention and Control of Major Diseases in the Population, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China
5 shared publicationsYichen Yang
Tianjin Cancer Institute, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Prevention and Control of Major Diseases in the Population, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China
5 shared publicationsHongru Shen
Tianjin Cancer Institute, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Key Laboratory of Cancer Immunology and Biotherapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
4 shared publications- Kexin Chen
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
4 shared publications - Xiangchun Li
Department of Public Laboratory, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University , Tianjin 300060
3 shared publications Chao Zhang
Tianjin Medical University Cancer Institute and Hospital
2 shared publications
Latest Publications
Photothermally Tunable Nano‐Fusogen Enables Spatiotemporally Controlled Membrane Resealing after Traumatic Spinal Cord Injury
Rapid restoration of membrane integrity represents a potential therapeutic approach to rescuing cells after traumatic spinal cord injury (TSCI). In contrast to endogenous repair mechanisms, which are often insufficient under severe injury conditions, synthetic membrane‐resealing materials offer substantial potential but remain constrained by limited control over membrane interactions and functional activation. Here, we show that mild hyperthermia markedly enhances the membrane‐resealing efficacy of polyethylene glycol (PEG), which may be associated with increased lipid bilayer fluidity and Annexin A1 expression. Based on these findings, we engineer a photothermal nano‐fusogen by conjugating PEG and cholesterol‐modified PEG onto gold nanorods, enabling targeted membrane insertion in vivo followed by near‐infrared–triggered localized heating to achieve efficient membrane repair. In a rat TSCI model, a single intraspinal administration of the nano‐fusogen combined with irradiation restores spinal cord compound action potentials, reduces lactate dehydrogenase release, suppresses cleaved caspase‐3 expression, and was accompanied by higher expression of selected membrane‐repair‐associated genes. Longitudinal analyses further demonstrate improved hindlimb locomotor recovery and enhanced neuronal survival. This work establishes a photothermally tunable nano‐fusogen platform for spatiotemporally controlled membrane repair and functional recovery after TSCI, with broader implications for acute injuries characterized by catastrophic membrane disruption.
Photothermally Tunable Nano‐Fusogen Enables Spatiotemporally Controlled Membrane Resealing after Traumatic Spinal Cord Injury
Rapid restoration of membrane integrity represents a potential therapeutic approach to rescuing cells after traumatic spinal cord injury (TSCI). In contrast to endogenous repair mechanisms, which are often insufficient under severe injury conditions, synthetic membrane‐resealing materials offer substantial potential but remain constrained by limited control over membrane interactions and functional activation. Here, we show that mild hyperthermia markedly enhances the membrane‐resealing efficacy of polyethylene glycol (PEG), which may be associated with increased lipid bilayer fluidity and Annexin A1 expression. Based on these findings, we engineer a photothermal nano‐fusogen by conjugating PEG and cholesterol‐modified PEG onto gold nanorods, enabling targeted membrane insertion in vivo followed by near‐infrared–triggered localized heating to achieve efficient membrane repair. In a rat TSCI model, a single intraspinal administration of the nano‐fusogen combined with irradiation restores spinal cord compound action potentials, reduces lactate dehydrogenase release, suppresses cleaved caspase‐3 expression, and was accompanied by higher expression of selected membrane‐repair‐associated genes. Longitudinal analyses further demonstrate improved hindlimb locomotor recovery and enhanced neuronal survival. This work establishes a photothermally tunable nano‐fusogen platform for spatiotemporally controlled membrane repair and functional recovery after TSCI, with broader implications for acute injuries characterized by catastrophic membrane disruption.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500204
Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection
PURPOSE: Gastric cancer (GC) is a significant global health challenge, often diagnosed late, limiting treatment success. Early detection through biomarkers is critical for better outcomes. This study developed a noninvasive, cost-effective tool using circulating cell-free DNA (cfDNA) sequencing and advanced modeling for early GC detection. METHODS: We performed low-coverage whole-genome sequencing on plasma from 404 patients with GC and 428 non-GC participants (healthy donors and patients with colorectal, esophageal, or liver cancer). Participants were divided into a training set (579) and a validation set (253). A deep learning model, GastricAI, was trained on raw cfDNA reads using Mamba, an advanced sequence model enhancing the structured state space model (S4) with adaptive parameters. Performance was evaluated in a second validation set (73 GC patients, 94 controls). RESULTS: In the first validation set, GastricAI achieved an area under receiver operating characteristic curve (AUROC) of 0.886 (95% CI, 0.842 to 0.930), accuracy of 0.846, sensitivity of 0.789, and specificity of 0.900. Across TNM stages, it recorded sensitivity/specificity of 0.920/0.738 (stage I), 0.846/0.900 (stage II), 0.811/0.900 (stage III), and 1.000/0.623 (stage IV). In the second validation set, it showed an AUROC of 0.850 (95% CI, 0.793 to 0.907), accuracy of 0.772, sensitivity of 0.973, and specificity of 0.617. GastricAI consistently detected intestinal, diffuse, and mixed GC subtypes per Lauren's classification and outperformed conventional biomarkers carbohydrate antigen 724 ( P < .001) and carcinoembryonic antigen ( P = .037). CONCLUSION: GastricAI provides a promising noninvasive method for GC detection via cfDNA sequencing, with high sensitivity and reasonable specificity. It holds potential for early screening to improve prognosis, although further prospective studies are needed to validate and refine its clinical utility across diverse populations.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500204
Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection
PURPOSE: Gastric cancer (GC) is a significant global health challenge, often diagnosed late, limiting treatment success. Early detection through biomarkers is critical for better outcomes. This study developed a noninvasive, cost-effective tool using circulating cell-free DNA (cfDNA) sequencing and advanced modeling for early GC detection. METHODS: We performed low-coverage whole-genome sequencing on plasma from 404 patients with GC and 428 non-GC participants (healthy donors and patients with colorectal, esophageal, or liver cancer). Participants were divided into a training set (579) and a validation set (253). A deep learning model, GastricAI, was trained on raw cfDNA reads using Mamba, an advanced sequence model enhancing the structured state space model (S4) with adaptive parameters. Performance was evaluated in a second validation set (73 GC patients, 94 controls). RESULTS: In the first validation set, GastricAI achieved an area under receiver operating characteristic curve (AUROC) of 0.886 (95% CI, 0.842 to 0.930), accuracy of 0.846, sensitivity of 0.789, and specificity of 0.900. Across TNM stages, it recorded sensitivity/specificity of 0.920/0.738 (stage I), 0.846/0.900 (stage II), 0.811/0.900 (stage III), and 1.000/0.623 (stage IV). In the second validation set, it showed an AUROC of 0.850 (95% CI, 0.793 to 0.907), accuracy of 0.772, sensitivity of 0.973, and specificity of 0.617. GastricAI consistently detected intestinal, diffuse, and mixed GC subtypes per Lauren's classification and outperformed conventional biomarkers carbohydrate antigen 724 ( P < .001) and carcinoembryonic antigen ( P = .037). CONCLUSION: GastricAI provides a promising noninvasive method for GC detection via cfDNA sequencing, with high sensitivity and reasonable specificity. It holds potential for early screening to improve prognosis, although further prospective studies are needed to validate and refine its clinical utility across diverse populations.
- 1 February 2024
- Published by Elsevier in Nano Today
- Vol. 55, 102173
Self-generated double-stranded RNA for enhancing tumor immunotherapy and metastasis inhibition
- 1 February 2024
- Published by Elsevier in Nano Today
- Vol. 55, 102173
Self-generated double-stranded RNA for enhancing tumor immunotherapy and metastasis inhibition
- 11 October 2023
- Published by SPIE-Intl Soc Optical Eng
- Vol. 12800, 83-88
A lightweight detection algorithm for steel surface defects based on improved YOLOv5
To address the issue of imbalanced complexity and precision in series models of YOLO, this paper proposes a lightweight object detection algorithm based on YOLOv5s as the baseline model, namely YOLOv5-SFD. Firstly, the PANet structure of YOLOv5s is simplified to the basic FPN, and a Locally Dense Connected Convolution (LDCC) is proposed to improve the problem of feature information loss during downsampling by cheap feature extraction and feature reuse. Secondly, the C3 module of the original model is improved based on LDCC and combined with the C3Ghost module to reduce the weight of the model. Finally, a bottleneck residual block, BLS (Bottleneck LDCC-SE), based on LDCC and Squeeze-and-Excitation attention is introduced to enhance the feature extraction capability of the network. On the dataset NEU-DET, compared to the baseline model, the precision, recall, F1 score, mAP@.5 and mAP@.5:.95 is 73.4%, 84.7%, 77%, 91.5% and 52.5%, respectively, which represents an improvement of 3.2%, 2.2%, 2%, 11.8%, and 4.5%. In addition, the number of parameters is reduced by approximately 47%, and the model size is only 55% of the baseline model. The experimental results demonstrate that YOLOv5-SFD has lower model complexity and higher detection accuracy, which meets the requirements of lightweight networks.
- 11 October 2023
- Published by SPIE-Intl Soc Optical Eng
- Vol. 12800, 83-88
A lightweight detection algorithm for steel surface defects based on improved YOLOv5
To address the issue of imbalanced complexity and precision in series models of YOLO, this paper proposes a lightweight object detection algorithm based on YOLOv5s as the baseline model, namely YOLOv5-SFD. Firstly, the PANet structure of YOLOv5s is simplified to the basic FPN, and a Locally Dense Connected Convolution (LDCC) is proposed to improve the problem of feature information loss during downsampling by cheap feature extraction and feature reuse. Secondly, the C3 module of the original model is improved based on LDCC and combined with the C3Ghost module to reduce the weight of the model. Finally, a bottleneck residual block, BLS (Bottleneck LDCC-SE), based on LDCC and Squeeze-and-Excitation attention is introduced to enhance the feature extraction capability of the network. On the dataset NEU-DET, compared to the baseline model, the precision, recall, F1 score, mAP@.5 and mAP@.5:.95 is 73.4%, 84.7%, 77%, 91.5% and 52.5%, respectively, which represents an improvement of 3.2%, 2.2%, 2%, 11.8%, and 4.5%. In addition, the number of parameters is reduced by approximately 47%, and the model size is only 55% of the baseline model. The experimental results demonstrate that YOLOv5-SFD has lower model complexity and higher detection accuracy, which meets the requirements of lightweight networks.
- Top Cited PapersOpen Access
- 25 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians. We perform single-cell RNA sequencing for 63,394 cells obtained from 5 acral and 3 cutaneous melanoma samples to investigate tumor heterogeneity and immune environment. We define 5 orthogonal functional cell clusters that are involved in TGF-beta signaling, Type I interferon, Wnt signaling, Cell cycle, and Cholesterol efflux signaling. Signatures of enriched TGF-beta, Type I interferon, and cholesterol efflux signaling are significantly associated with good prognosis of melanoma. Compared with cutaneous melanoma, acral melanoma samples have significantly severe immunosuppressive state including depletion of cytotoxic CD8+ T cells, enrichment of Treg cells, and exhausted CD8+ T cells. PD1 and TIM-3 have higher expression in the exhaustive CD8+ T cells of acral melanoma. Key findings are verified in two independent validation sets. This study contributes to our better understanding of acral melanoma.
- 25 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Top Cited PapersOpen AccessA single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma
Acral melanoma is a dismal subtype of melanoma occurring in glabrous acral skin, and has a higher incidence in East Asians. We perform single-cell RNA sequencing for 63,394 cells obtained from 5 acral and 3 cutaneous melanoma samples to investigate tumor heterogeneity and immune environment. We define 5 orthogonal functional cell clusters that are involved in TGF-beta signaling, Type I interferon, Wnt signaling, Cell cycle, and Cholesterol efflux signaling. Signatures of enriched TGF-beta, Type I interferon, and cholesterol efflux signaling are significantly associated with good prognosis of melanoma. Compared with cutaneous melanoma, acral melanoma samples have significantly severe immunosuppressive state including depletion of cytotoxic CD8+ T cells, enrichment of Treg cells, and exhausted CD8+ T cells. PD1 and TIM-3 have higher expression in the exhaustive CD8+ T cells of acral melanoma. Key findings are verified in two independent validation sets. This study contributes to our better understanding of acral melanoma.
- Open Access
- 10 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 996293
Prognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy
Purpose: We aim to explore whether the gross volume of metastatic lymph nodes (GTVnd) and the gross volume of primary tumor (GTVp) could be prognostic factors for esophageal squamous cell carcinoma (ESCC) patients treated with definitive concurrent chemoradiotherapy (dCCRT).Methods: We retrospectively analyzed 252 ESCC patients treated with dCCRT in the era of intensity-modulated radiation therapy (IMRT) at our institution. The cut-off value for the GTVnd derived from the restricted cubic splines (RCS) was determined. Univariate and multivariate Cox proportional hazard models were performed to determine the association between GTVnd and prognosis. we performed recursive partitioning analysis (RPA) method using GTVnd to develop a new risk stratification (TGTVndM). Moreover, the linear trend χ2, likelihood ratio χ2, and akaike information criterion (AIC) were used to determine the prognostic value between the TNM and TGTVndM staging systems.Results: The five-year overall survival (OS) rate was 30.6%, with a median follow-up of 38 months. The cut-off value of GTVnd determined by the RCS was 4.35 cm3. GTVnd≥4.35 cm3 was an independent and significant negative prognostic factor for OS (HR=1.949, P<0.001), progression free survival (PFS) (HR=1.425, P=0.048), and distance metastasis free survival (DMFS) (HR=2.548, P=0.001). In multivariable analysis, gender, clinical T stage, and GTVnd were independently associated with OS. RPA segregated patients into 3 prognostic groups: high risk (T1-4 GTVnd≥4.35, n=126, III stage), intermediate risk (T4 GTVnd<4.35,n=38,II stage), and low risk(T1-3GTVnd<4.35, n=88, I stage). The 5-year OS(P<0.001), PFS (P=0.002), and DMFS (P=0.001) were significantly worse in high-risk group in comparison with the intermediate and low risk groups. Compared with the TNM staging system, the clinical T stage combined with GTVnd (TGTVndM) had a higher linear trend χ2 (26.38 versus 25.77), higher likelihood ratio χ2 (24.39 versus 20.69), and lower AIC (1255.07 versus 1260.06).Conclusions: GTVnd may serve as a good prognostic factor in predicting distant metastasis and death for ESCC patients treated with dCCRT. The TGTVndM staging system demonstrated superior accuracy for predicting OS and could serve as a more effective prognostic guidance for unresectable ESCC patients.
- 10 November 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 996293
Open AccessPrognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy
Purpose: We aim to explore whether the gross volume of metastatic lymph nodes (GTVnd) and the gross volume of primary tumor (GTVp) could be prognostic factors for esophageal squamous cell carcinoma (ESCC) patients treated with definitive concurrent chemoradiotherapy (dCCRT).Methods: We retrospectively analyzed 252 ESCC patients treated with dCCRT in the era of intensity-modulated radiation therapy (IMRT) at our institution. The cut-off value for the GTVnd derived from the restricted cubic splines (RCS) was determined. Univariate and multivariate Cox proportional hazard models were performed to determine the association between GTVnd and prognosis. we performed recursive partitioning analysis (RPA) method using GTVnd to develop a new risk stratification (TGTVndM). Moreover, the linear trend χ2, likelihood ratio χ2, and akaike information criterion (AIC) were used to determine the prognostic value between the TNM and TGTVndM staging systems.Results: The five-year overall survival (OS) rate was 30.6%, with a median follow-up of 38 months. The cut-off value of GTVnd determined by the RCS was 4.35 cm3. GTVnd≥4.35 cm3 was an independent and significant negative prognostic factor for OS (HR=1.949, P<0.001), progression free survival (PFS) (HR=1.425, P=0.048), and distance metastasis free survival (DMFS) (HR=2.548, P=0.001). In multivariable analysis, gender, clinical T stage, and GTVnd were independently associated with OS. RPA segregated patients into 3 prognostic groups: high risk (T1-4 GTVnd≥4.35, n=126, III stage), intermediate risk (T4 GTVnd<4.35,n=38,II stage), and low risk(T1-3GTVnd<4.35, n=88, I stage). The 5-year OS(P<0.001), PFS (P=0.002), and DMFS (P=0.001) were significantly worse in high-risk group in comparison with the intermediate and low risk groups. Compared with the TNM staging system, the clinical T stage combined with GTVnd (TGTVndM) had a higher linear trend χ2 (26.38 versus 25.77), higher likelihood ratio χ2 (24.39 versus 20.69), and lower AIC (1255.07 versus 1260.06).Conclusions: GTVnd may serve as a good prognostic factor in predicting distant metastasis and death for ESCC patients treated with dCCRT. The TGTVndM staging system demonstrated superior accuracy for predicting OS and could serve as a more effective prognostic guidance for unresectable ESCC patients.
- Open Access
- 29 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-8
Deep learning to diagnose Hashimoto’s thyroiditis from sonographic images
Hashimoto’s thyroiditis (HT) is the main cause of hypothyroidism. We develop a deep learning model called HTNet for diagnosis of HT by training on 106,513 thyroid ultrasound images from 17,934 patients and test its performance on 5051 patients from 2 datasets of static images and 1 dataset of video data. HTNet achieves an area under the receiver operating curve (AUC) of 0.905 (95% CI: 0.894 to 0.915), 0.888 (0.836–0.939) and 0.895 (0.862–0.927). HTNet exceeds radiologists’ performance on accuracy (83.2% versus 79.8%; binomial test, p < 0.001) and sensitivity (82.6% versus 68.1%; p < 0.001). By integrating serologic markers with imaging data, the performance of HTNet was significantly and marginally improved on the video (AUC, 0.949 versus 0.888; DeLong’s test, p = 0.004) and static-image (AUC, 0.914 versus 0.901; p = 0.08) testing sets, respectively. HTNet may be helpful as a tool for the management of HT.
- 29 June 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-8
Open AccessDeep learning to diagnose Hashimoto’s thyroiditis from sonographic images
Hashimoto’s thyroiditis (HT) is the main cause of hypothyroidism. We develop a deep learning model called HTNet for diagnosis of HT by training on 106,513 thyroid ultrasound images from 17,934 patients and test its performance on 5051 patients from 2 datasets of static images and 1 dataset of video data. HTNet achieves an area under the receiver operating curve (AUC) of 0.905 (95% CI: 0.894 to 0.915), 0.888 (0.836–0.939) and 0.895 (0.862–0.927). HTNet exceeds radiologists’ performance on accuracy (83.2% versus 79.8%; binomial test, p < 0.001) and sensitivity (82.6% versus 68.1%; p < 0.001). By integrating serologic markers with imaging data, the performance of HTNet was significantly and marginally improved on the video (AUC, 0.949 versus 0.888; DeLong’s test, p = 0.004) and static-image (AUC, 0.914 versus 0.901; p = 0.08) testing sets, respectively. HTNet may be helpful as a tool for the management of HT.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1326
Abstract 1326: Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33
Recent studies suggest p53 contributes to poor survival in the context of immune checkpoint blockade (ICB). Mutations to p53 significantly improve the response rate to PD-1 ICB in lung cancer patients. Tumor-derived IL-33 is required for the anti-tumor immune response and efficacy of ICB. However, the relationship between p53 and IL-33 during ICB is unknown. In this study, we characterize the role of the p53/IL-33 axis in regulating the response of the tumor microenvironment to ICB. We use CRISPR-Cas9 to delete Trp53 from murine MC38 colon adenocarcinoma. Deletion of Trp53 and PD-1 ICB synergistically inhibits tumor growth. Il33 is upregulated in the Trp53-deficient and treated tumor cells, and its expression increases with time and response to treatment. Cd4+ and Cd8+ T cell infiltration increases adjacent to IL-33 expressing tumor cells, while Treg infiltration is decreased. Simultaneous deletion of Il33 in MC38 tumors reverses the efficacy PD-1 ICB. Trp53-deficient MC38 in ST2-/- (IL-33 receptor) mice also show no response to PD-1 ICB. Our findings depict a novel mechanism by which the loss of p53 in tumors treated with ICB unleashes the expression of tumoral IL-33 and induces downstream signaling. p53 mutations may be a double-edged sword for cancer, i.e. the loss of the tumor suppressor initially facilitates tumorigenesis, but eventual buildup of mutations and activation of damage pathways, such as NF-kB, leads to upregulation of danger signals in the tumor. These danger signals, such as IL-33, mediate the anti-tumor effect of ICB. Citation Format: David Shihong Gao, Yang Li, Jason Shoush, Runzi Sun, Binfeng Lu. Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1326.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1326
Open AccessAbstract 1326: Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33
Recent studies suggest p53 contributes to poor survival in the context of immune checkpoint blockade (ICB). Mutations to p53 significantly improve the response rate to PD-1 ICB in lung cancer patients. Tumor-derived IL-33 is required for the anti-tumor immune response and efficacy of ICB. However, the relationship between p53 and IL-33 during ICB is unknown. In this study, we characterize the role of the p53/IL-33 axis in regulating the response of the tumor microenvironment to ICB. We use CRISPR-Cas9 to delete Trp53 from murine MC38 colon adenocarcinoma. Deletion of Trp53 and PD-1 ICB synergistically inhibits tumor growth. Il33 is upregulated in the Trp53-deficient and treated tumor cells, and its expression increases with time and response to treatment. Cd4+ and Cd8+ T cell infiltration increases adjacent to IL-33 expressing tumor cells, while Treg infiltration is decreased. Simultaneous deletion of Il33 in MC38 tumors reverses the efficacy PD-1 ICB. Trp53-deficient MC38 in ST2-/- (IL-33 receptor) mice also show no response to PD-1 ICB. Our findings depict a novel mechanism by which the loss of p53 in tumors treated with ICB unleashes the expression of tumoral IL-33 and induces downstream signaling. p53 mutations may be a double-edged sword for cancer, i.e. the loss of the tumor suppressor initially facilitates tumorigenesis, but eventual buildup of mutations and activation of damage pathways, such as NF-kB, leads to upregulation of danger signals in the tumor. These danger signals, such as IL-33, mediate the anti-tumor effect of ICB. Citation Format: David Shihong Gao, Yang Li, Jason Shoush, Runzi Sun, Binfeng Lu. Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1326.
- Open Access
- 25 October 2021
- Published by Springer Nature in Research Square
A single-cell atlas reveals tumor heterogeneity and immune environment of acral melanoma
Acral melanoma is a dismal subtype of melanoma occurring at the extremities of dark-skinned people. We performed single-cell RNA sequencing for 63,394 cells obtained from 5 acral and 3 cutaneous melanoma samples to investigate tumor cellular ecosystem particularly the heterogeneity and immune environment. We defined 5 orthogonal cell clusters that were involved in TGF-beta signaling, Type I interferon, Wnt signaling, Cell cycle, and Cholesterol efflux signaling. Signatures of TGF-beta signaling and cholesterol efflux are significantly associated with prognosis of melanoma. Compared with cutaneous melanoma, acral melanoma samples had significantly severe immunosuppressive state including depletion of cytotoxic CD8 + T cells, enrichment of Treg cells, and exhausted CD8 + T cells. PDCD1 (PD-1) and HAVCR2 (TIM-3) had higher expression in the exhaustive CD8 + T cells of acral melanoma. In summary, we have uncovered the tumor heterogeneity and immune infiltration characteristics of acral melanoma. Our findings may help to understand and guide the immunotherapy of acral melanoma.
- 25 October 2021
- Published by Springer Nature in Research Square
Open AccessA single-cell atlas reveals tumor heterogeneity and immune environment of acral melanoma
Acral melanoma is a dismal subtype of melanoma occurring at the extremities of dark-skinned people. We performed single-cell RNA sequencing for 63,394 cells obtained from 5 acral and 3 cutaneous melanoma samples to investigate tumor cellular ecosystem particularly the heterogeneity and immune environment. We defined 5 orthogonal cell clusters that were involved in TGF-beta signaling, Type I interferon, Wnt signaling, Cell cycle, and Cholesterol efflux signaling. Signatures of TGF-beta signaling and cholesterol efflux are significantly associated with prognosis of melanoma. Compared with cutaneous melanoma, acral melanoma samples had significantly severe immunosuppressive state including depletion of cytotoxic CD8 + T cells, enrichment of Treg cells, and exhausted CD8 + T cells. PDCD1 (PD-1) and HAVCR2 (TIM-3) had higher expression in the exhaustive CD8 + T cells of acral melanoma. In summary, we have uncovered the tumor heterogeneity and immune infiltration characteristics of acral melanoma. Our findings may help to understand and guide the immunotherapy of acral melanoma.
- Open Access
Miscell: An efficient self-supervised learning approach for dissecting single-cell transcriptome